ReviewCurrent medicinal chemistry2025
The Role of Nutraceuticals in Chemoprevention and their Therapeutic Effects when used in Combination with Synthetic Drugs.
Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SIRT1: Protean roles at the nexus of health, disease, and therapeutics.Journal of cell communication and signaling · 2026Article
- Dietary bioactive compounds targeting insulin resistance: mechanisms and preventive potential.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, increasing attention has been directed toward nutraceuticals, natural substances extracted from plants, fruits, or cereals. These compounds are well-known for their antibacterial, anti-inflammatory, antioxidant, and antitumor properties, with the latter being the primary focus of this review. The use of nutraceuticals, both as standalone treatments and in combination with standard chemotherapy, has been extensively studied through in vitro, in vivo experiments, and clinical trials for the prevention and treatment of various types of cancer, including breast, colon, pancreatic, prostate cancers, and leukemia. Findings from these studies emphasize the benefits of nutraceuticals in improving patient compliance and mitigating the adverse effects of conventional drugs. Specifically, the combination of nutraceuticals with chemotherapy allows for reduced dosages of synthetic drugs, thereby lessening their often-severe side effects. In this review, we explore the diverse mechanisms of action underlying the antitumor activity of key nutraceuticals-including curcumin, resveratrol, tocotrienols, ursolic acid, fisetin, gambogic acid, catechins, silibinin, berberine, emodin, piperine, deguelin, garcinol, plumbagin, zerumbone, and ginger. Furthermore, we summarize the most significant outcomes from clinical trials investigating these compounds. The clinical studies addressed various aspects of treatment, such as efficacy, safety, maximum tolerated doses, potential adverse effects, and patient compliance. The majority of the findings highlight the positive impact of combining nutraceuticals with chemotherapy, demonstrating enhanced therapeutic outcomes in anticancer treatments.
Indexed as
Identifiers
39945263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.